RedHill Biopharma Ltd. is Preparing for an Advanced Clinical Trial with RHB-102, a Drug for the Prevention of Nausea and Vomiting in Cancer Patients Undergoing Chemotherapy and Radiotherapy

Published: Nov 03, 2011

TEL AVIV, Israel--(BUSINESS WIRE)--RedHill Biopharma Ltd. (TASE: RDHL), an emerging Israeli biopharmaceutical company focusing primarily on development and acquisition of late clinical-stage new formulations and combinations of existing drugs, reported an engagement with Algorithme Pharma, Inc. a Canadian CRO (Clinical Research Organization), for the execution of an advanced clinical trial with RHB-102, a drug designated to prevent chemotherapy and radiotherapy induced nausea and vomiting.

Back to news